Medtronic extravascular icd global clinical trial results reinforce device safety and effectiveness

Late-breaking data at heart rhythm 2023 underscore performance of first-of-its-kind investigational defibrillator with the lead placed under the breastbone, outside the heart and veins additionally, real-world analysis confirms long-term therapeutic benefit of commercially available icds dublin and new orleans , may 20, 2023 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, announced longer-term follow-up results of its investigational ev icd™ system, designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest. findings from the extravascular implantable cardioverter defibrillator (ev icd) pivotal study, including patients followed through an average of 17.1 months, were presented as late-breaking science at heart rhythm 2023 in new orleans.
MDT Ratings Summary
MDT Quant Ranking